In the case of gastric cancer, Liu et al. demonstrated that cells pretreated with a combination of ERK1/2 and p38 inhibitors could enhance the anti-proliferative effects of 5-FU via suppressing the ERCC1 (Excision Repair Cross Complementation group 1) protein [29]. Here, ERCC1 is linked to gastric cancer.